Threshold Pharmaceuticals Announces a Presentation At the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
27. Mai 2009 08:45 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 27, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302....
Threshold Pharmaceuticals Reports First Quarter 2009 Financial Results
07. Mai 2009 08:35 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 7, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the first quarter ended March 31, 2009.
The net loss for the...
Threshold Pharmaceuticals Presents Positive TH-302 Preclinical Results in Three Scientific Presentations At AACR Annual Meeting
20. April 2009 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 20, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced multiple preclinical presentations on its clinical stage hypoxia-activated...
Threshold Pharmaceuticals Announces Multiple Presentations At the 2009 American Association for Cancer Research (AACR) Annual Meeting
14. April 2009 09:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 14, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced multiple presentations on its hypoxia-activated prodrug, TH-302. The...
Threshold Pharmaceuticals Announces Going Concern Opinion
19. März 2009 08:30 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 19, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that its audited financial statements for the fiscal year ended December 31,...
Threshold Pharmaceuticals Announces Upcoming Presentation On TH-302 At the New York Academy of Sciences Hypoxia Meeting
11. März 2009 08:30 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 11, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Charles P. Hart, Ph.D., Vice President of Biology, will present at the New...
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
05. März 2009 08:30 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 5, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the fourth quarter and the year ended December 31,...
Threshold to Present At BIO CEO & Investor Conference On February 9
05. Februar 2009 08:55 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Feb. 5, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Barry Selick, Ph.D., Chief Executive Officer, will present at the BIO CEO...
Threshold Pharmaceuticals Appoints Dr. Jeffrey W. Bird to Board of Directors
19. November 2008 16:05 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 19, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that the Company has appointed Dr. Jeffrey W. Bird to its board of directors. Dr....
Threshold to Present At the Lazard Capital Markets Annual Healthcare Conference
13. November 2008 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it will present at the Lazard Capital Markets 5th Annual Healthcare...